---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-287710"
form_type: "8-K"
ticker: null
cik: "0001797336"
company_name: "Ayala Pharmaceuticals, Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:49:15.826858+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ayala Pharmaceuticals receives Nasdaq deficiency notices for equity <$10M and bid price below $1.00

## Summary
- Stockholders' equity as of Sep 30, 2022 was ~$8.16M, below Nasdaq's $10M minimum.
- Bid price closed below $1.00 for 30 consecutive business days as of Nov 16, 2022.
- Company has until Dec 27, 2022 to submit a plan for equity compliance; until May 15, 2023 for bid price.
- Options include transferring to Nasdaq Capital Market; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001193125-22-287710
- form_type: 8-K
- cik: 0001797336
- company_name: Ayala Pharmaceuticals, Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/0001193125-22-287710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/d360152d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-287710
- JSON: https://secwatch.observer/filing/0001193125-22-287710.json
- Plain text: https://secwatch.observer/filing/0001193125-22-287710.txt

## Key facts
- Listing & Compliance Notices
  Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: November 10, 2022, Ayala Pharmaceuticals, Inc. (the “Company”) received written notice (the “Equity Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of S
  evidence_url: https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/0001193125-22-287710-index.htm
- Listing & Compliance Notices
  Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: November 16, 2022, the Company received written notice (the “Bid Price Notice” and, together with the Equity Notice, the “Notices”) from Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notices have no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market and the Company’s common s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/0001193125-22-287710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.